J. F. Blanc, J. C. Barbare, A. S. Baumann, V. Boige, K. Boudjema et al., Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worlwide for 36 cancers in 185 countries, A Cancer Journal for Clinicians, vol.2, issue.6, pp.394-324, 1990.

, EASL guidelines : European Association For The Study Of The Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma, Journal of Hepatology, vol.4, pp.182-236, 2018.

J. M. Llovet, C. Brú, and J. Bruix, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin Liver Dis, vol.19, pp.329-339, 1999.

K. Takayasu, S. Arii, I. Ikai, M. Omata, K. Okita et al., Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients, Gastroenterology, vol.131, pp.461-469, 2006.

J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology, vol.42, issue.5, pp.1208-1236

C. M. Lo, H. Ngan, and W. K. Tso, Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectablehepatocellular carcinoma, Hepatology, vol.35, pp.1164-1171, 2002.

J. M. Llovet, M. I. Real, X. Montana, C. Cammà, F. Schepis et al., Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial, Radiology, vol.359, issue.1, pp.47-54, 2002.

J. M. Llovet, J. Bruix, G. S. Roth, T. Decaens, J. C. Barbare et al., Screening for Vulnerability in Older Cancer Patients : The ONCODAGE. Prospective Multicenter Cohort Study, Systematic review of randomized trials for unresectable hepatocellular carcinoma : chemoembolization improves survival, vol.11, pp.1115-1123, 1994.

K. Dohmen, M. Shirahama, H. Shigematsu, K. Irie, and H. Ishibashi, Optimal treatment strategy for elderly patients with hepatocellular carcinoma, J Gastroenterol Hepatol, vol.19, pp.859-865, 2004.

T. Yau, T. J. Yao, P. Chan, R. J. Epstein, K. K. Ng et al., Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database, Safety and Prognosis of Transarterial Chemoembolization for Octogenarians with Hepatocellular Carcinoma, vol.115, pp.1413-1419, 2005.

:. U. Pamoukdjian, F. Canoui-poitrine, F. Longelin-lombard, C. Aparicio, T. Ganne et al., Diagnostic performance of gait speed, G8 and G8 modified indices to screen for vulnerability in older cancer patients : the prospective PF-EC cohort study, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), vol.29, pp.50393-50402, 2017.

M. J. Song, H. J. Chun, D. S. Song, H. Y. Kim, S. H. Yoo et al., Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma, PRECISION V Investigators. Prospective randomized study of doxorubicin-elutingbead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study, vol.33, p.46, 2010.

Q. Yang, J. X. Ye, and F. , Safety and efficacy analysis of DEB-TACE treatment in elderly patients with hepatocellular carcinoma : a comparative cohort study, 2018.

E. B. Levy, V. P. Krishnasamy, A. L. Lewis, S. Willis, C. Macfarlane et al., TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib, Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC) : multi-center results on safety and efficacy, vol.34, pp.72613-72620, 2016.